Abstract 2059P
Background
Two decades ago medication related osteonecrosis of the jaw (MRONJ) was first described in oncology pts receiving BMAs. Pre-existing dental disease is the main initiating factor for MRONJ. Dental disease is the commonest global non-communicable disease. We assessed the impact of integrating a dental oncology service for all incident pts prescribed BMAs.
Methods
A dental clinic was established in March 2022 collocated with a cancer centre and all pts receiving BMAs were assessed by an oral surgeon prior to BMA administration and all necessary dental treatment was completed.
Results
120 pts included (66% female), 66 were <65 years, were treated over 1 year. 82 pts had metastatic disease. Early stage breast cancer (N=35), metastatic breast cancer (N=36), prostate cancer (N=24), and other malignancies (N=25) were represented in this cohort. 118 pts were planned for intravenous zoledronate and 2 were planned for denosumab. 117 pts were deemed dentally fit to commence their BMA. 29 pts were current smokers, and 24 pts wore dentures. 45 pts had a current dental complaint on presentation, for which 31 complaints related to pain and infection. Assessment of barriers to dental services; 20 pts live alone, 42 pts were not registered with a dentist, and 51 hadn’t seen their dentist in ≥3 yrs. 8 pts had intraoral smoking related changes, and moderate dysplasia was identified in 1 pt following a biopsy. The Decayed, Missing and Filled Teeth (DMFT) index median score was 18, and mean DMFT score was 19. 88 pts had a periodontal status of ≥Stage 2 Grade B which demonstrated longstanding and active periodontal disease. The mean bleeding on probing score was 35% and 75 pts had a high Caries Risk Assessment score. 65 pts required an operative dental procedure. 33 pts received a dental restoration, of which 16 pts required a median of 2 dental restorations. 58 pts had teeth extracted, of whom 37 had a median of 3 teeth extracted.
Conclusions
This oncology cohort had poor engagement with dentistry and had a high burden of dental disease prior to BMA treatment. The data highlights their dental treatment needs prior to BMA treatment and the requirement for proactive dental integration by the oncology team. Dental care should be an integral part of multidisciplinary cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
CiSA.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2066P - Evaluation of the quality and reliability of ChatGPT and Perplexity's responses about rectal cancer
Presenter: Ozan Yazici
Session: Poster session 06
2067P - Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data
Presenter: Tomi Kovacevic
Session: Poster session 06
2068P - Perspectives and concerns on sexuality among adolescents and young adults treated for testicular germ cell tumour: The PRICELESS-study - A qualitative study
Presenter: Danielle Zweers
Session: Poster session 06
2069P - QoL changes of caregivers during first-line palliative chemotherapy for patients with incurable cancer
Presenter: Nobumichi Takeuchi
Session: Poster session 06
2070P - Assessment of healthy lifestyle habits in breast cancer patients
Presenter: Juan Cristobal Sanchez
Session: Poster session 06
2071P - Identification of top issues and concerns of cancer patients in Korea on social media
Presenter: Joo Han Lim
Session: Poster session 06
2072P - Topical application of mixed agents to reduce oral mucositis during radiotherapy in post operated head and neck cancer
Presenter: Chandra Prakash
Session: Poster session 06
2073P - Medical cannabis: A potential effective treatment for chemotherapy-induced peripheral neuropathy (CIPN)
Presenter: Ravit Geva
Session: Poster session 06
2074P - Oral cannabidiol for prevention of chemotherapy-induced peripheral neuropathy
Presenter: Sebastian Nielsen
Session: Poster session 06